Domestic formulations lift Glenmark's third quarter revenues
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has reported a 17% increase in revenues to Rs7.50 billion ($165.3 million) for the third quarter ended 31 December 2010, buoyed by growth in the domestic formulations business.